Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03JFC
|
|||
Former ID |
DNC014111
|
|||
Drug Name |
3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate
|
|||
Synonyms |
CHEMBL573871; 3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C17H16N2O3
|
|||
Canonical SMILES |
CCCNC(=O)OC1=CC=CC(=C1)C2=NC3=CC=CC=C3O2
|
|||
InChI |
1S/C17H16N2O3/c1-2-10-18-17(20)21-13-7-5-6-12(11-13)16-19-14-8-3-4-9-15(14)22-16/h3-9,11H,2,10H2,1H3,(H,18,20)
|
|||
InChIKey |
VWTFAQPOTOAJGW-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
BioCyc | Anandamide degradation | |||
KEGG Pathway | Retrograde endocannabinoid signaling | |||
Panther Pathway | Anandamide degradation |
References | Top | |||
---|---|---|---|---|
REF 1 | Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and int... Eur J Med Chem. 2009 Oct;44(10):4179-91. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.